Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexsero Immune Response to Gonorrhea
NCT04094883Phase 4Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meningococcal group B vaccine in gonorrhea, sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin G (IgG) Concentrations at Week 7, Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin M (IgM) Concentrations at Week 7 and 2 more. Started Oct 2019; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT04094883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094883.